Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.
OBJECTIVE
Lanreotide is a novel synthetic somatostatin analogue. A long-acting formulation of lanreotide has been shown to be effective for the treatment of gastroentero-pancreatic hormone-producing tumours but effects on postprandial digestive and absorptive functions remain obscure. The aim of the present study was to evaluate the effects of intravenous lanreotide on gastric and biliopancreatic secretions in man as well as the absorption of nutrients and the duodeno-caecal transit time after ingestion of an homogenized meal (500 kcal, 55% carbohydrates, 15% proteins, 30% lipids).


METHODS
Eight healthy male volunteers were studied on two occasions within a 2 weeks interval, using a perfusion method. They received in single-blind and random order continuous i.v. infusion of either placebo or lanreotide (100 micrograms h-t after a bolus of 100 micrograms 15 min before the beginning of the study).


RESULTS
Lanreotide significantly decreased gastric acid secretion (90%) for the initial 3 h period. Gastric emptying was not significantly modified by lanreotide infusion. Compared with placebo, lanreotide almost completely abolished both bile salts and lipase responses to the meal. It largely increased the duodeno-caecal transit time and decreased significantly the duodenal absorption of carbohydrates and triglycerides.


CONCLUSIONS
Since lanreotide has powerful effects on gastrointestinal functions, it could be useful in the prevention or in the treatment of pancreatic and bowel fistulas as well as short bowel syndrome.
Lamrani
A
A
Laboratoire de Recherche en Pathologie Digestive, Université René Descartes and Service d'Hépato-Gastroentérologie, Hôpital Cochin, Paris, France.
Vidon
N
N
Sogni
P
P
Nepveux
P
P
Catus
F
F
Blumberg
J
J
Chaussade
S
S
D000328:Adult; D000890:Anti-Infective Agents / Q000097:blood; D018592:Cross-Over Studies; D005744:Gastric Acid / Q000378:metabolism*; D005746:Gastric Emptying / Q000187:drug effects; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D010179:Pancreas / Q000378:metabolism; D010456:Peptides, Cyclic / Q000493:pharmacokinetics* / Q000494:pharmacology; D010477:Perfusion; D011092:Polyethylene Glycols / Q000008:administration & dosage; D019518:Postprandial Period / Q000187:drug effects; D012044:Regression Analysis; D016037:Single-Blind Method; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D013427:Sulfapyridine / Q000097:blood; D012460:Sulfasalazine / Q000008:administration & dosage
D000890:Anti-Infective Agents; D005765:Gastrointestinal Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D011092:Polyethylene Glycols; D012460:Sulfasalazine; D013004:Somatostatin; D013427:Sulfapyridine